Jahn I., Eberle A., Niehues C., Birn A., Horch K. Gesundheitsberichterstattung
des Bundes, Gebärmuttererkrankungen. Heft 37, Robert Koch-Institut; 2007
Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi
F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005 Apr;
6 (4): 204.
Baseman J. G., Koutsky L. A. The epidemiology of human papillomavirus
infections. J Clin Virol. 2005 Mar; 32 Suppl 1: S16-24.
Bosch F., de Sanjosé S., Castellsagué X., Moreno V., Muñoz N. Epidemiology
of human papillomavirus infections and associations with cervical cancer:
New opportunities for prevention. In Papillomavirus Research: From Natural
History To Vaccines and Beyond. M Campo, ed (Wymondham, Caister Academic
Press). 2006: 19-39.
Manhart L. E., Holmes K. K., Koutsky L. A., Wood T. R., Kenney D. L.,
Feng Q., et al. Human papillomavirus infection among sexually active young
women in the United States: Implications for developing a vaccination
strategy. Sex Transm Dis. 2006 Aug; 33 (8): 502-8.
Partridge J. M., Koutsky L. A. Genital human papillomavirus infection
in men. Lancet Infect Dis. 2006 Jan; 6 (1): 21-31.
Carter J. J., Koutsky L. A., Wipf G. C., Christensen N. D., Lee S. K.,
Kuypers J., et al. The natural history of human papillomavirus type 16
capsid antibodies among a cohort of university women. J Infect Dis. 1996
Nov; 174 (5): 927-36.
Klug S. J., Hukelmann M., Hollwitz B., Duzenli N., Schopp B., Petry
K. U., et al. Prevalence of human papillomavirus types in women screened
by cytology in Germany. J Med Virol. 2007 May; 79 (5): 616-25.
Petry K. U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho
Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical
cancer screening for women above 29 years in Germany: results for 8466
patients. Br J Cancer. 2003 May 19; 88 (10): 1570-7.
Schneider A., Hoyer H., Lotz B., Leistritza S., Kuhne-Heid R., Nindl
I., et al. Screening for high-grade cervical intra-epithelial neoplasia
and cancer by testing for high-risk HPV, routine cytology or colposcopy.
Int J Cancer. 2000 Nov 20; 89 (6): 529-34.
Trottier H., Franco E. L. The epidemiology of genital human papillomavirus
infection. Vaccine. 2006 Mar 30; 24 Suppl 1: S1-15.
Ho G. Y., Bierman R., Beardsley L., Chang C. J., Burk R. D. Natural
history of cervicovaginal papillomavirus infection in young women. N Engl
J Med. 1998 Feb 12; 338 (7): 423-8.
Nobbenhuis M. A., Helmerhorst T. J., van den Brule A. J., Rozendaal
L., Voorhorst F. J., Bezemer P. D., et al. Cytological regression and
clearance of 47 high-risk human papillomavirus in women with an abnormal
cervical smear. Lancet. 2001 Nov 24; 358 (9295): 1782-3.
Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005 Mar; 32
Suppl 1: S7-15.
Longworth M. S., Laimins L. A. Pathogenesis of human papillomaviruses
in differentiating epithelia. Microbiol Mol Biol Rev. 2004 Jun; 68 (2):
362-72.
Durst M., Glitz D., Schneider A., zur Hausen H. Human papillomavirus
type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia:
analysis by in situ hybridization. Virology. 1992 Jul; 189 (1): 132-40.
Demeter L. M., Stoler M. H., Broker T. R., Chow L. T. Induction of proliferating
cell nuclear antigen in differentiated keratinocytes of human papillomavirusinfected
lesions. Hum Pathol. 1994 Apr; 25 (4): 343-8.
Munger K., Howley P. M. Human papillomavirus immortalization and transformation
functions. Virus Res. 2002 Nov; 89 (2): 213-28.
Bohmer G., van den Brule A. J., Brummer O., Meijer C. L., Petry K. U.
No confirmed case of human papillomavirus DNA-negative cervical intraepithelial
neoplasia grade 3 or invasive primary cancer of the uterine cervix among
511 patients. Am J Obstet Gynecol. 2003 Jul; 189 (1): 118-20.
Snijders P. J., van den Brule A. J., Meijer C. J. The clinical relevance
of human papillomavirus testing: relationship between analytical and clinical
sensitivity. J Pathol. 2003 Sep; 201 (1): 1-6.
FUTURE II STUDY GROUP. Quadrivalent vaccine against human papillomavirus
to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10; 356
(19): 1915-27.
Munoz N., Bosch F. X., de Sanjose S., Herrero R., Castellsague X., Shah
K. V., et al. Epidemiologic classification of human papillomavirus types
associated with cervical cancer. N Engl J Med. 2003 Feb 6; 348 (6): 518-27.
Walboomers J. M., Jacobs M. V., Manos M. M., Bosch F. X., Kummer J.
A., Shah K. V., et al. Human papillomavirus is a necessary cause of invasive
cervical cancer worldwide. J Pathol. 1999 Sep; 189 (1): 12-9.
Statistisches Bundesamt. Gesundheitswesen, Todesursachen in Deutschland
2004. Fachserie 12 / Reihe 4, Statistisches Bundesamt; 2005
Richart R. M. Natural history of cervical intraepithelial neoplasia.
Clin Obstet Gynecol. 1968; 10: 748-84.
Hampl M., Sarajuuri H., Wentzensen N., Bender H. G., Kueppers V. Effect
of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial
lesions and vulvar cancer. Obstet Gynecol. 2006 Dec; 108 (6): 1361-8.
Petry K. U., Bohmer G., Iftner T., Davies P., Brummer O., Kuhnle H.
Factors associated with an increased risk of prevalent and incident grade
III cervical intraepithelial neoplasia and invasive cervical cancer among
women with Papanicolaou tests classified as grades I or II cervical intraepithelial
neoplasia. Am J Obstet Gynecol. 2002 Jan; 186 (1): 28-34.
Creasman W. T. Vaginal cancers. Curr Opin Obstet Gynecol. 2005 Feb;
17 (1): 71-6.48
Cupp M. R., Malek R. S., Goellner J. R., Smith T. F., Espy M. J. The
detection of human papillomavirus deoxyribonucleic acid in intraepithelial,
in situ, verrucous and invasive carcinoma of the penis. J Urol. 1995 Sep;
154 (3): 1024-9.
Dillner J., Meijer C. J., von Krogh G., Horenblas S. Epidemiology of
human papillomavirus infection. Scand J Urol Nephrol Suppl. 2000; (205):
194-200.
Rubin M. A., Kleter B., Zhou M., Ayala G., Cubilla A. L., Quint W. G.,
et al. Detection and typing of human papillomavirus DNA in penile carcinoma:
evidence for multiple independent pathways of penile carcinogenesis. Am
J Pathol. 2001 Oct; 159 (4): 1211-8.
Frisch M., Fenger C., van den Brule A. J., Sorensen P., Meijer C. J.,
Walboomers J. M., et al. Variants of squamous cell carcinoma of the anal
canal and perianal skin and their relation to human papillomaviruses.
Cancer Res. 1999 Feb 1; 59 (3): 753-7.
Fox P. A. Human papillomavirus and anal intraepithelial neoplasia. Curr
Opin Infect Dis. 2006 Feb; 19 (1): 62-6.
Gross G., Barrasso R. Human Papillomavirus Infection. A Clinical Atlas.
Wiesbaden, Berlin: Ullstein-Mosby; 1997; ISBN: 3-86126-117-0.
Gross G., Pfister H. Role of human papillomavirus in penile cancer,
penile intraepithelial squamous cell neoplasias and in genital warts.
Med Microbiol Immunol. 2004 Feb; 193 (1): 35-44.
Gross G., Ikenberg H., Gissmann L., Hagedorn M. Papillomavirus infection
of the anogenital region: correlation between histology, clinical picture,
and virus type. Proposal of a new nomenclature. J Invest Dermatol. 1985
Aug; 85 (2): 147-52.
Lacey C. J. Therapy for genital human papillomavirus-related disease.
J Clin Virol. 2005 Mar; 32 Suppl 1: S82-90.
Gross G., Ikenberg H., Petry K. U., Pfister H., Schneede P., Schofer
H., et al. [Condyloma acuminata and other HPV-associated diseases of the
genitals, anus and urethra]. Hautarzt. 2007 Feb; 58 (2): 179-86.
Krogh von, Lacey C. J., Gross G., Barrasso R., Schneider A. European
Course on HPV Associated Pathology (ECHPV), European Branch of the International
Union against Sexually Transmitted Infection and the European Office of
the World Health Organization. Int J STD AIDS. 2001; 12 Suppl 3: 40-7.
Lowy D. R., Howley P. M. Papillomavirus replication. In Fields Virology,
1th ed (Philadelphia, Lippincott Williams & Wilkins). 2001: 2231-64.
Armstrong L. R., Preston E. J., Reichert M., Phillips D. L., Nisenbaum
R., Todd N. W., et al. Incidence and prevalence of recurrent respiratory
papillomatosis among children in Atlanta and Seattle. Clin Infect Dis.
2000 Jul; 31 (1): 107-9.
Wiatrak B. J. Overview of recurrent respiratory papillomatosis. Curr
Opin Otolaryngol Head Neck Surg. 2003 Dec; 11 (6): 433-41.
Kreimer A. R., Clifford G. M., Boyle P., Franceschi S. Human papillomavirus
types in head and neck squamous cell carcinomas worldwide: a systematic
review. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14 (2): 467-75.49
Herrero R., Castellsague X., Pawlita M., Lissowska J., Kee F., Balaram
P., et al. Human papillomavirus and oral cancer: the International Agency
for Research on Cancer multicenter study. J Natl Cancer Inst. 2003 Dec
3; 95 (23): 1772-83.
D'Souza G., Kreimer A. R., Viscidi R., Pawlita M., Fakhry C., Koch W.
M., et al. Case-control study of human papillomavirus and oropharyngeal
cancer. N Engl J Med. 2007 May 10; 356 (19): 1944-56.
Mork J., Lie A. K., Glattre E., Hallmans G., Jellum E., Koskela P.,
et al. Human papillomavirus infection as a risk factor for squamous-cell
carcinoma of the head and neck. N Engl J Med. 2001 Apr 12; 344 (15): 1125-31.
Smith E. M., Ritchie J. M., Summersgill K. F., Hoffman H. T., Wang D.
H., Haugen T. H., et al. Human papillomavirus in oral exfoliated cells
and risk of head and neck cancer. J Natl Cancer Inst. 2004 Mar 17; 96
(6): 449-55.
Reimers N., Kasper H. U., Weissenborn S. J., Stutzer H., Preuss S. F.,
Hoffmann T. K., et al. Combined analysis of HPV-DNA, p16 and EGFR expression
to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007 Apr 15;
120 (8): 1731-8.
Fakhry C., Gillison M. L. Clinical implications of human papillomavirus
in head and neck cancers. J Clin Oncol. 2006 Jun 10; 24 (17): 2606-11.
Smeets S. J., Hesselink A. T., Speel E. J., Haesevoets A., Snijders
P. J., Pawlita M., et al. A novel algorithm for reliable detection of
human papillomavirus in paraffin embedded head and neck cancer specimen.
Int J Cancer. 2007 Dec 1; 121 (11): 2465-72.
Becker N. Epidemiological aspects of cancer screening in Germany. J
Cancer Res Clin Oncol. 2003 Dec; 129 (12): 691-702.
Hakama M., Miller A. B., Day N. E. Screening for cancer of the uterine
cervix. IARC Scientific Publications. 1986; 76 (Lyon).
IARC. Cervix cancer screening. IARC Handbooks of Cancer Prevention.
2005; 10 (Lyon).
Villa L. L., Costa R. L., Petta C. A., Andrade R. P., Ault K. A., Giuliano
A. R., et al. Prophylactic quadrivalent human papillomavirus (types 6,
11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised
double-blind placebocontrolled multicentre phase II efficacy trial. Lancet
Oncol. 2005 May; 6 (5): 271-8.
Block S. L., Nolan T., Sattler C., Barr E., Giacoletti K. E., Marchant
C. D., et al. Comparison of the immunogenicity and reactogenicity of a
prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18)
L1 virus-like particle vaccine in male and female adolescents and young
adult women. Pediatrics. 2006 Nov; 118 (5): 2135-45.
Giannini S. L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy
F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18
L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04)
compared to aluminium salt only. Vaccine. 2006 Aug 14; 24 (33-34): 5937-49.50
Breitburd F., Kirnbauer R., Hubbert N. L., Nonnenmacher B., Trin-Dinh-Desmarquet
C., Orth G., et al. Immunization with viruslike particles from cottontail
rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.
J Virol. 1995 Jun; 69 (6): 3959-63.
Harper D. M., Franco E. L., Wheeler C., Ferris D. G., Jenkins D., Schuind
A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention
of infection with human papillomavirus types 16 and 18 in young women:
a randomised controlled trial. Lancet. 2004 Nov 13-19; 364 (9447): 1757-65.
Fife K. H., Wheeler C. M., Koutsky L. A., Barr E., Brown D. R., Schiff
M. A., et al. Dose-ranging studies of the safety and immunogenicity of
human papillomavirus Type 11 and Type 16 virus-like particle candidate
vaccines in young healthy women. Vaccine. 2004 Jul 29; 22 (21-22): 2943-52.
Robert Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO)
am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für
Mädchen von 12 bis 17 Jahren - Empfehlung und Begründung. Epidemiologisches
Bulletin. 12, 2007
Garland S. M., Hernandez-Avila M., Wheeler C. M., Perez G., Harper D.
M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus
to prevent anogenital diseases. N Engl J Med. 2007 May 10; 356 (19): 1928-43.
Koutsky L. A., Ault K. A., Wheeler C. M., Brown D. R., Barr E., Alvarez
F. B., et al. A controlled trial of a human papillomavirus type 16 vaccine.
N Engl J Med. 2002 Nov 21; 347 (21): 1645-51.
Mao C., Koutsky L. A., Ault K. A., Wheeler C. M., Brown D. R., Wiley
D. J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical
intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol.
2006 Jan; 107 (1): 18-27.
Paavonen J., Jenkins D., Bosch F. X., Naud P., Salmeron J., Wheeler
C. M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle
vaccine against infection with human papillomavirus types 16 and 18 in
young women: an interim analysis of a phase III double-blind, randomised
controlled trial. Lancet. 2007 Jun 30; 369 (9580): 2161-70.
Villa L. L., Costa R. L., Petta C. A., Andrade R. P., Paavonen J., Iversen
O. E., et al. High sustained efficacy of a prophylactic quadrivalent human
papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through
5 years of follow-up. Br J Cancer. 2006 Dec 4; 95 (11): 1459-66.
Harper D. M., Franco E. L., Wheeler C. M., Moscicki A. B., Romanowski
B., Roteli-Martins C. M., et al. Sustained efficacy up to 4.5 years of
a bivalent L1 virus-like particle vaccine against human papillomavirus
types 16 and 18: followup from a randomised control trial. Lancet. 2006
Apr 15; 367 (9518): 1247-55.
Joura E. A., Leodolter S., Hernandez-Avila M., Wheeler C. M., Perez
G., Koutsky L. A., et al. Efficacy of a quadrivalent prophylactic human
papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine
against high-grade vulval and vaginal lesions: a combined analysis of
three randomised clinical trials. Lancet. 2007 May 19; 369 (9574): 1693-702.
Giroglou T., Sapp M., Lane C., Fligge C., Christensen N. D., Streeck
R. E., et al. Immunological analyses of human papillomavirus capsids.
Vaccine. 2001 Feb 8; 19 (13-14): 1783-93.51
Smith J. F., Brownlow M., Brown M., Kowalski R., Esser M. T., Ruiz W.,
et al. Antibodies from Women Immunized with Gardasil ((R)) Cross-Neutralize
HPV 45 Pseudovirions. Hum Vaccin. 2007 Jul-Aug; 3 (4): 109-16.
Petry K.U., Hillemanns P., Gieseking F., Littlewood K.J., Büsch K.,
Breugelmans J.G. Direkte und indirekte Kostenbewertungen HPV-assoziierter
Erkrankungen (Genitalwarzen und zervikale Läsionen ) in Deutschland, 15
Jahrestagung der Deutschen Gesellschaft für Pädiatrische Infektiologie,
2007, Basel, Poster P68.
Hillemanns P., Petry K. U., McAllister R., Büsch K., Largeron N. Vortrag
zu: HPV (6, 11, 16 & 18)-Impfung als Primärprävention bei HPV-bedingten
Erkrankungen - eine Kosteneffektivitätsanalyse in Deutschland. (Informationsquelle:
Sanofi MSD). 2007
Parkin D. M. The global health burden of infection-associated cancers
in the year 2002. Int J Cancer. 2006 Jun 15; 118 (12): 3030-44.
Emeny R. T., Wheeler C. M., Jansen K. U., Hunt W. C., Fu T. M., Smith
J. F., et al. Priming of human papillomavirus type 11-specific humoral
and cellular immune responses in college-aged women with a virus-like
particle vaccine. J Virol. 2002 Aug; 76 (15): 7832-42.
Gross G. [Impact of prophylactic HPV vaccines on dermatology and venereology].
Hautarzt. 2007 Jun; 58 (6): 507-14.
Gieseking F. Incidence, prevalence and costsof treating genital warts
in the pre-HPV vaccine era in Germany. Value Health. 2005; 8: 64-5.
Kreuter A., Brockmeyer N. H., Hochdorfer B., Weissenborn S. J., Stucker
M., Swoboda J., et al. Clinical spectrum and virologic characteristics
of anal intraepithelial neoplasia in HIV infection. J Am Acad Dermatol.
2005 Apr; 52 (4): 603-8.
Roka S., Rasoul-Rockenschaub S., Roka J., Kirnbauer R., Muhlbacher F.,
Salat A. Prevalence of anal HPV infection in solid-organ transplant patients
prior to immunosuppression. Transpl Int. 2004 Aug; 17 (7): 366-9.
Busnach G., Piselli P., Arbustini E., Baccarani U., Burra P., Carrieri
M. P., et al. Immunosuppression and cancer: A comparison of risks in recipients
of organ transplants and in HIV-positive individuals. Transplant Proc.
2006 Dec; 38 (10):3533-5.
Schwarz T. F., Dubin G. O. An AS 04-containing human papillomavirus
(HPV) 16/18 vaccine for prevention of cervical cancer in immunogenic and
welltolerated in women 15-55 years old. Journal of Clinical Oncology,
2006 ACSO Annual Meeting Proceedings (Post-Meeting Edition). 2006 June
20; 24 (18 Suppl). 52
Hernan M. A., Alonso A., Hernandez-Diaz S. Tetanus vaccination and risk
of multiple sclerosis: a systematic review. Neurology. 2006 Jul 25; 67
(2): 212-5.
Gloster H. M., Jr., Roenigk R. K. Risk of acquiring human papillomavirus
from the plume produced by the carbon dioxide laser in the treatment of
warts. J Am Acad Dermatol. 1995 Mar; 32 (3): 436-41.
Sawchuk W. S., Weber P. J., Lowy D. R., Dzubow L. M. Infectious papillomavirus
in the vapor of warts treated with carbon dioxide laser or electrocoagulation:
detection and protection. J Am Acad Dermatol. 1989 Jul; 21 (1): 41-9.
Barrett W. L., Garber S. M. Surgical smoke: a review of the literature.
Is this just a lot of hot air? Surg Endosc. 2003 Jun; 17 (6): 979-87.